scholarly article | Q13442814 |
P356 | DOI | 10.1016/0140-6736(91)90943-J |
P698 | PubMed publication ID | 1671232 |
P50 | author | Martin Rowe | Q37376494 |
Stephen Hamilton-Dutoit | Q42323196 | ||
P2093 | author name string | L S Young | |
G Pallesen | |||
P433 | issue | 8737 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Epstein–Barr virus | Q6900 |
P304 | page(s) | 320-322 | |
P577 | publication date | 1991-02-01 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease | |
P478 | volume | 337 |
Q61718413 | 3D Telomere FISH defines LMP1-expressing Reed–Sternberg cells as end-stage cells with telomere-poor ‘ghost’ nuclei and very short telomeres |
Q72838637 | A 26-year-old man with Hodgkin's disease and rapidly progressive pancytopenia |
Q51011838 | A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses. |
Q45771274 | A pathologic study of Hodgkin's disease in Korea and its association with Epstein-Barr virus infection |
Q35121627 | A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer |
Q35872919 | A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle |
Q35831803 | A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas |
Q45736315 | Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma |
Q26782845 | Adoptive T-Cell Immunotherapy |
Q55240614 | Adult T-Cell Leukaemia-Lymphoma Relapsing as Hodgkin Disease Nodular Sclerosis Subtype. |
Q73101619 | Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease |
Q73227618 | An immunohistochemical analysis of Reed-Sternberg-like cells in posttransplantation lymphoproliferative disorders: the possible pathogenetic relationship to Reed-Sternberg cells in Hodgkin's disease and Reed-Sternberg-like cells in non-Hodgkin's lym |
Q42937211 | Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site |
Q40958134 | Anaplastic large cell lymphoma: update of findings |
Q73006577 | Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12 |
Q45879859 | Antibodies to human herpes virus‐6 and clinical course in patients with Hodgkin's disease |
Q45753261 | Antibody against the Epstein-Barr virus BHRF1 protein, a homologue of Bcl-2, in patients with nasopharyngeal carcinoma |
Q73572578 | Apoptosis of malignant cells in Hodgkin's disease is related to expression of the cdk inhibitor p27KIP1 |
Q33748089 | Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo |
Q36623027 | Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease |
Q45402221 | Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: a pathological and virological study |
Q35833017 | Association of Epstein-Barr virus with pediatric Hodgkin's disease. |
Q36370843 | Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma |
Q35549146 | B cells under influence: transformation of B cells by Epstein–Barr virus |
Q35110895 | Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases |
Q33772230 | Biology and disease associations of Epstein-Barr virus |
Q40548687 | Biopathologic features of Hodgkin's disease |
Q35232770 | CD23 and the Epstein-Barr virus |
Q45400120 | CD4(+) T-cell responses to Epstein-Barr virus (EBV) latent membrane protein 1 in infectious mononucleosis and EBV-associated non-Hodgkin lymphoma: Th1 in active disease but Tr1 in remission |
Q42754645 | CD40 expression in Hodgkin's disease |
Q40180827 | Cancer Risk After Pediatric Solid Organ Transplantation |
Q42663880 | Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. |
Q39539494 | Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils |
Q61718416 | Chromosomal rearrangements after ex vivo Epstein–Barr virus (EBV) infection of human B cells |
Q35237191 | Clinicopathological spectrum of Epstein-Barr virus-associated T cell malignancies |
Q45787074 | Co-expression of Epstein-Barr virus latent membrane protein and vimentin in "aggressive" histological subtypes of Hodgkin's disease |
Q45710976 | Comparison of Epstein-Barr Virus Presence in Hodgkin Lymphoma in Pediatric Versus Adult Argentine Patients |
Q38900959 | Comparison of Epstein-Barr virus markers in Reed-Sternberg cells in adult Hodgkin's disease tissues from an industrialized and a developing country |
Q36059593 | Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer |
Q36105462 | Comprehensive profiling of functional Epstein-Barr virus miRNA expression in human cell lines. |
Q37016499 | Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. |
Q36464566 | Control of viral disease: the development of Epstein-Barr virus vaccines |
Q41342184 | Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity |
Q35831438 | Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease |
Q33852518 | Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview |
Q36399791 | Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease |
Q36651589 | Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. |
Q41607034 | Deletion variants within the NF-kappaB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations |
Q40848861 | Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease |
Q42755159 | Demonstration of a unique Epstein-Barr virus-positive cellular clone in metachronous multiple localizations of Hodgkin's disease |
Q38337443 | Deregulation of the cell cycle machinery by Epstein-Barr virus nuclear antigen 3C. |
Q40684609 | Detection and characterization of Epstein-Barr virus in clinical specimens. |
Q40994216 | Detection and quantification of Epstein-Barr virus EBER1 in EBV-infected cells by fluorescent in situ hybridization and flow cytometry |
Q35831898 | Detection of Epstein-Barr virus genome in Ki-1 (CD30)-positive, large-cell anaplastic lymphomas using the polymerase chain reaction |
Q37138731 | Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age |
Q30656075 | Detection of Epstein-Barr virus in archival Hodgkin's disease specimens |
Q45747752 | Detection of Epstein-Barr virus in invasive breast cancers. |
Q38483042 | Detection of Epstein-Barr virus small RNAs in routine paraffin sections using non-isotopic RNA/RNA in situ hybridization. |
Q45761154 | Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein |
Q35017860 | Diagnosis of Epstein-Barr virus-associated diseases |
Q81828786 | Diagnostic accuracy of imprint cytology in the assessment of Hodgkin's disease in Japan |
Q39658596 | Dynamic chromosomal rearrangements in Hodgkin's lymphoma are due to ongoing three-dimensional nuclear remodeling and breakage-bridge-fusion cycles |
Q50567063 | EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction. |
Q43225878 | EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency |
Q53024631 | EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products |
Q33987454 | EBV latency types adopt alternative chromatin conformations |
Q37589686 | EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults |
Q51735191 | EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. |
Q42911133 | EBV-associated recurrent Hodgkin's disease after renal transplantation |
Q37268348 | EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier |
Q43790916 | EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru |
Q45735503 | Editorial comment on detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction by Wagner and colleagues |
Q36617871 | Effect of material deprivation on Epstein-Barr virus infection in Hodgkin's disease in the West Midlands |
Q36207395 | Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice |
Q38375380 | Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis |
Q41490952 | Encoded latent membrane protein 1 of Epstein-Barr virus on follicular dendritic cells in residual germinal centres in Hodgkin's disease |
Q41475508 | Epstein Barr virus in Argentine pediatric Hodgkin's disease |
Q45788351 | Epstein barr virus (EBV)‐carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPS but not EBNA2 in vivo |
Q38257974 | Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis |
Q59354936 | Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice |
Q45736201 | Epstein-Barr Virus-Associated Cholangiocarcinoma with Lymphoepithelioma-Like Component. |
Q36653989 | Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. |
Q43478753 | Epstein-Barr virus (EBV) in Chinese pediatric Hodgkin disease: Hodgkin disease in young children is an EBV-related lymphoma |
Q40958139 | Epstein-Barr virus (EBV) in extranodal T-cell non-Hodgkin's lymphomas (T-NHL). Identification of nasal T-NHL as a distinct clinicopathological entity associated with EBV. |
Q24670596 | Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations |
Q40126382 | Epstein-Barr virus (EBV) provides survival factors to EBV+ diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV+ DLBCL. |
Q45746241 | Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1. |
Q39604074 | Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. |
Q35764233 | Epstein-Barr virus LMP1 modulates the malignant potential of gastric carcinoma cells involving apoptosis. |
Q35831567 | Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study |
Q38322174 | Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells |
Q33906890 | Epstein-Barr virus and Hodgkin's lymphoma in Cairo, Egypt |
Q43049278 | Epstein-Barr virus and human hepatocellular carcinoma |
Q56947843 | Epstein-Barr virus and nasopharyngeal carcinoma |
Q34221194 | Epstein-Barr virus and oncogenesis: from latent genes to tumours |
Q44909702 | Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma |
Q40475844 | Epstein-Barr virus as an agent of haematological disease. |
Q45748229 | Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population |
Q36641073 | Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function |
Q41601147 | Epstein-Barr virus genes and cancer cells |
Q45860535 | Epstein-Barr virus in AIDS-related primary central nervous system lymphoma |
Q45783366 | Epstein-Barr virus in Hodgkin's disease and site of origin of tumour |
Q41979291 | Epstein-Barr virus in adult T-cell leukemia/lymphoma. |
Q35833192 | Epstein-Barr virus in pyothorax-associated pleural lymphoma |
Q45753650 | Epstein-Barr virus in the pathogenesis of Hodgkin's disease |
Q35833510 | Epstein-Barr virus infection and bcl-2 proto-oncogene expression. Separate events in the pathogenesis of Hodgkin's disease? |
Q44036511 | Epstein-Barr virus infection and response to radiotherapy in squamous cell carcinoma of the oral cavity |
Q34576340 | Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions |
Q42451168 | Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia |
Q38356037 | Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity |
Q40040836 | Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells |
Q41594644 | Epstein-Barr virus oncogenesis |
Q40620396 | Epstein-Barr virus persistence and virus-associated tumours |
Q45459307 | Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings |
Q45785122 | Epstein-Barr virus-associated hemophagocytic syndrome |
Q44406598 | Epstein-Barr virus-associated large granular lymphocyte leukemia with cutaneous infiltration |
Q34651670 | Epstein-Barr virus-associated lymphomas. |
Q40507895 | Epstein-Barr virus-associated non-Hodgkin's lymphoma in HIV-infected patients |
Q35076846 | Epstein-Barr virus-recent advances |
Q45744350 | Epstein-Barr virus: Co-opting B-cell memory and migration |
Q34572150 | Epstein-Barr virus: exploiting the immune system |
Q38968588 | Epstein-Barr virus: more than 50 years old and still providing surprises. |
Q39444685 | Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma |
Q33899102 | Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications |
Q45789695 | Epstein‐Barr virus in nasal T‐cell lymphomas (polymorphic reticulosis/midline malignant reticulosis) in Western China |
Q40445894 | Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. |
Q36119183 | Evidence of an oncogenic gammaherpesvirus in domestic dogs |
Q71739027 | Evolution of Hodgkin's disease |
Q37072931 | Exposures to multiple pesticides and the risk of Hodgkin lymphoma in Canadian men |
Q40848717 | Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus infection |
Q43768398 | Expression of EBV encoded latent membrane protein 1 (LMP-1) and bcl-2 protein in childhood and adult Hodgkin's disease: application of microwave irradiation for antigen retrieval |
Q42197461 | Expression of Epstein-Barr virus encoded latent genes in nasal T cell lymphomas |
Q41809459 | Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas |
Q45754776 | Expression of Epstein-Barr virus in patients with Hodgkin's disease in Taiwan. |
Q45787321 | Expression of bcl‐2 protein and transcription of the Epstein‐Barr virus bcl‐2 homologue BHRF‐1 in Hodgkin's disease: implications for different pathogenic mechanisms |
Q39610559 | Expression of c-myc and bcl-2 oncogene products in Reed-Sternberg cells independent of presence of Epstein-Barr virus |
Q72052148 | Expression of c‐myc and c‐ras oncogenes in the neoplastic and non‐neoplastic cells of Hodgkin's disease |
Q40868229 | Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status |
Q38462802 | Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells |
Q28213139 | Fascin expression in CD30-positive cutaneous lymphoproliferative disorders |
Q34435311 | Follicular dendritic cell sarcoma mimicking diffuse large cell lymphoma: a case report |
Q92775971 | Follicular dendritic cells display microvesicle-associated LMP1 in reactive germinal centers of EBV+ classic Hodgkin lymphoma |
Q45146767 | Frequency of Epstein-Barr virus expression in various histological subtypes of Hodgkin's lymphoma |
Q45730504 | Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells |
Q36784912 | Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy |
Q33810034 | Gammaherpesviruses and "Hit-and-Run" oncogenesis |
Q35764932 | Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein |
Q40489810 | Genetically Engineered Tumor Vaccines |
Q33778708 | HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma |
Q38330937 | Heat shock factor 1 upregulates transcription of Epstein-Barr Virus nuclear antigen 1 by binding to a heat shock element within the BamHI-Q promoter |
Q50863201 | Hemophagocytic syndrome associated with hematological neoplasias. |
Q41047224 | Hepatitis C virus and non-Hodgkin's lymphomas |
Q43529854 | Hepatosinusoidal leukaemia/lymphoma consisting of Epstein-Barr virus-containing natural killer cell leukaemia/lymphoma and T-cell lymphoma; mimicking malignant histiocytosis |
Q45750564 | High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease |
Q45778505 | High frequency of Epstein-Barr virus in Chinese peripheral T-cell lymphoma |
Q35832700 | High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease |
Q24535291 | Hodgkin's disease and the Epstein-Barr virus |
Q40413265 | Hodgkin's disease: a monoclonal lymphoproliferative disorder? |
Q41107614 | Hodgkin's disease: old and recent clinical concepts |
Q35640337 | Hodgkin's lymphoma, Epstein-Barr virus reactivation and fatal haemophagocytic syndrome |
Q36564877 | Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs |
Q35103531 | How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus |
Q24302204 | Human cellular protein VRK2 interacts specifically with Epstein-Barr virus BHRF1, a homologue of Bcl-2, and enhances cell survival |
Q24683663 | Human herpesvirus 6 |
Q40401808 | Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors |
Q33640213 | IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter |
Q45732919 | Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. |
Q36669953 | Immune regulation in Epstein-Barr virus-associated diseases |
Q37902694 | Immunocytochemistry: an indispensable technique in routine cytology |
Q41217111 | Immunology of Hodgkin's disease |
Q33561185 | Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034 |
Q56903494 | Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma |
Q36449583 | Immunovirology of transforming viruses |
Q35395693 | Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases |
Q42522230 | In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas |
Q53702693 | In vivo production of interleukin-10 by malignant cells in AIDS lymphomas. |
Q45778254 | Infection by Epstein-Barr virus in Hodgkin's disease is not restricted to the Reed-Sternberg cells |
Q41115991 | Infectious agents and environmental factors in lymphoid malignancies |
Q45786981 | Influence of Epstein-Barr virus encoded latent membrane protein 1 on the expression of CD23 antigen, ICAM-1 and LFA-3 in Hodgkin and Reed-Sternberg cells. A morphometric analysis |
Q39950750 | Influence of Epstein-Barr virus infection in adult T-cell leukemia |
Q35892261 | Interferon-independent and -induced regulation of Epstein-Barr virus EBNA-1 gene transcription in Burkitt lymphoma. |
Q39400493 | LMP1 and Dynamic Progressive Telomere Dysfunction: A Major Culprit in EBV-Associated Hodgkin's Lymphoma |
Q35539719 | LMP1 mediates multinuclearity through downregulation of shelterin proteins and formation of telomeric aggregates. |
Q34430225 | LMP1-induced downregulation of CD99 molecules in Hodgkin and Reed-Sternberg cells |
Q36292321 | Lack of involvement of known oncogenic DNA viruses in Epstein-Barr virus-negative Hodgkin's disease. |
Q43464160 | Lack of restricted T-cell receptor beta-chain variable region (V beta) usage of reactive T-lymphocytes in Hodgkin's disease |
Q40912121 | Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease |
Q36231451 | Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development |
Q35888992 | Localization of predisposition to Hodgkin disease in the HLA class II region. |
Q35763601 | Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group |
Q36361402 | Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines |
Q45737162 | Marked decrease in the Epstein-Barr virus positivity rate in nodular sclerosis subtype Hodgkin's disease in Tokyo: trend between 1955 and 1999. |
Q39585366 | Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation |
Q45770516 | Miliary tuberculosis in a patient with Epstein-Barr virus-associated angioimmunoblastic lymphadenopathy |
Q45759860 | Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus |
Q36464514 | Molecular basis for Epstein-Barr virus induced pathogenesis and disease |
Q34225554 | Molecular virology of Epstein-Barr virus |
Q72428154 | Monocytoid B-cells occurring in Hodgkin's disease |
Q45784460 | Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus |
Q22254088 | NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells |
Q35938397 | Nasal angiocentric lymphoma with hemophagocytic syndrome |
Q46826933 | Neoplastic cells of Hodgkin's disease show differences in EBV expression between Kenya and Italy |
Q28316608 | Neurotoxic treatment in a patient with brachial neuritis associated with Hodgkin's disease |
Q35178930 | New Testing Approaches in Transfusion Medicine |
Q35137170 | New candidate virus in association with Hodgkin's disease. |
Q35796270 | New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin's disease |
Q35228687 | Non-Hodgkin's lymphomas and paraproteinaemias |
Q37461346 | Nuclear factor-κB2 represses Sp1-mediated transcription at the CD99 promoter |
Q45756797 | Oncogene expression in tumour cells of pediatric Hodgkin's disease in Argentina--correlation with Epstein Barr virus presence. |
Q64086953 | Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders |
Q60920748 | Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases |
Q35618780 | Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells |
Q35026045 | Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders |
Q41217096 | Pathophysiology of Hodgkin's disease: functional and molecular aspects |
Q41136153 | Pediatric cancer: environmental and genetic aspects |
Q45769830 | Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus |
Q39826959 | Phosphatidylinositol 3-kinase/Akt pathway targets acetylation of Smad3 through Smad3/CREB-binding protein interaction: contribution to transforming growth factor beta1-induced Epstein-Barr virus reactivation |
Q33589790 | Practical applications of immunohistochemistry in hematolymphoid neoplasms |
Q35831247 | Presence of Epstein-Barr virus in Hodgkin's disease is not exclusive to Reed-Sternberg cells |
Q39992915 | Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma |
Q35858283 | Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases |
Q48116228 | Primary central nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: expression of cellular surface proteins and Epstein-Barr viral markers |
Q37111224 | Primary cerebral lymphoma: a study of 47 cases probed for Epstein-Barr virus genome |
Q35991951 | Primary cutaneous plasmacytoma after rejection of a transplanted kidney: case report and review of the literature |
Q37741123 | Rare Clinical Sign of Hodgkin's Lymphoma: Ocular Involvement |
Q37004635 | Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reed-Sternberg cell |
Q35239255 | Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material |
Q42013581 | Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen. |
Q36464560 | Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases |
Q35848189 | Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus |
Q40794281 | Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity. |
Q45785307 | Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression |
Q36641491 | Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents |
Q43517544 | Routine detection of Epstein-Barr virus specific T-cells in the peripheral blood by flow cytometry |
Q37366527 | STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma |
Q39737614 | Short-circuiting long-lived humoral immunity by the heightened engagement of CD40. |
Q35239264 | Significance of the detection of Epstein-Barr virus DNA in lymph nodes in patients with Hodgkin's disease |
Q36623552 | South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease |
Q35609768 | T cell-based therapies for EBV-associated malignancies |
Q37948940 | T-cell therapies for Epstein-Barr virus-associated lymphomas |
Q45729409 | Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma |
Q35874869 | The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element |
Q33882153 | The Epstein-Barr virus and its association with human cancers |
Q35576612 | The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates. |
Q40958145 | The antigen-presenting cell function of Reed-Sternberg cells |
Q45749636 | The association of latent Epstein-Barr virus infection with hydroa vacciniforme |
Q41305118 | The association of the Epstein-Barr virus with malignant lymphoma |
Q30670726 | The cellular protein PRA1 modulates the anti-apoptotic activity of Epstein-Barr virus BHRF1, a homologue of Bcl-2, through direct interaction |
Q40782239 | The cytoplasmic amino-terminus of the Latent Membrane Protein-1 of Epstein-Barr Virus: relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain |
Q41036904 | The ecology and pathology of Epstein-Barr virus |
Q41217081 | The epidemiology of Hodgkin's disease |
Q53859468 | The evidence of human herpesvirus 6 infection in the lymph nodes of Hodgkin's disease. |
Q34089485 | The expression and function of Epstein-Barr virus encoded latent genes |
Q35795114 | The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders |
Q40843575 | The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell |
Q72341488 | The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood |
Q36686042 | The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. |
Q36470749 | The next wave of recombinant and synthetic anticancer vaccines |
Q36685081 | The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential |
Q33925488 | The role of EBV in post-transplant malignancies: a review |
Q34798881 | The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas |
Q41553353 | The role of Epstein-Barr virus in lymphoid malignancies |
Q40857915 | The role of Epstein-Barr virus subtypes in human immunodeficiency virus-associated lymphoma |
Q35854017 | Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein |
Q36135900 | Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells |
Q34554722 | Treatment of Epstein-Barr virus-associated malignancies with specific T cells |
Q96303449 | Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome |
Q45772460 | Undifferentiated carcinoma of the parotid gland in a white patient: detection of Epstein-Barr virus by in situ hybridization |
Q35798133 | Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia |
Q39736781 | Unexpected absence of the Epstein-Barr virus (EBV) lyLMP-1 open reading frame in tumor virus isolates: lack of correlation between Met129 status and EBV strain identity |
Q45730476 | Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood |
Q33852513 | Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: with emphasis on EB virus, human herpesvirus 6 and hepatitis C virus |
Q38363351 | Viruses and Hodgkin disease: no evidence of novel herpesviruses in non-EBV-associated lesions. |
Q40486562 | What is the Origin of the Malignant Cell in Hodgkin's Disease? |
Search more.